Protein pompa inhibitörleri esomeprazol ve pantoprazol KML hücrelerinin imatinibe karşı kemosensitivitesini artırmaktadır

birlikte son yıllarda PPİ’lerin tek başlarına veya kemoterapötik ajanlarla kombine halde kullanımlarının önemli antikanser etkiye sahip olduğu bildirilmektedir. Bu çalışmanın amacı esomeprazol ve pantaprazol’ün tek başlarına antikanser etkili olup olmadıklarının veya KML hücrelerinin imatinibe karşı hassasiyetini artırıp artırmayacağının araştırılmasıdır. Yöntem: İnsan kronik miyeloid lösemi (KML) hücreleri kültüre edildi ve hücrelere farklı konsantrasyonlarda esomeprazol, pantoprazol ve imatinib tek başlarına uygulandı. Ayrıca hücreler üzerine imatinib + esomeprazol ve imatinib + pantoprazol kombinasyonları ayrı ayrı uygulanarak 24 saat inkübe edildi. PPİ’lerin tek başına ve imatinib ile kombinasyonlarına ait antiproliferatif aktiviteleri XTT testi ile değerlendirildi. Bulgular: Deneysel verilere göre her iki PPİ de 500 ve 1000 μM hariç uygulanan bütün dozlarda K562 hücreleri üzerinde herhangi bir sitotoksisite göstermemiştir. Bununla birlikte imatinib ile ayrı ayrı kombine edildiklerinde, imatinibin tek başına uygulandığı gruba göre K562 hücreleri üzerinde önemli antikanser etkilerinin olduğu belirlenmiştir (p

Protein pump inhibitors esomeprazole and pantoprazole increase the chemosensitivity of Cml cells against imatinib

Objective: Proton pump inhibitors (PPIs) largely used drug to treat gastroesophageal disease such as gastric ulcers.Moreover, in recent years, several studies suggest that PPIs have important anti-cancer effect in monotherapy and orcombination with chemotherapy.The aim of this study was to investigate whether esomeprazole and pantoprazole exhibit anti-cancer effect alone orcould enhance chemosensitivity of CML cell line K562 to imatinib.Method: Human chronic myeloid leukemia (CML) cells were cultured and treated with different concentrations ofesomeprazole, pantoprazole, and imatinib alone. Also these cells exposed to imatinib + esomeprazole and imatinib +pantoprazole combinations, respectively and incubated 24 h. The antiproliferative activities of the (PPIs) alone or incombination of imatinib was evaluated using the XTT colorimetric assay.Results: According to experimental data, neither PPIs showed any cytotoxicity on the K562 cell line at allconcentrations except at 500 and 1000 μM. However, when combined with imatinib separately, they were found to havesignificant anti-cancer effects on K562 cells when compared to cell lines treated with imatinib alone (p

PDF

___

Ergül M, Ergül M, Tutar Y. Important Anti- Cancer Applications of Protein Based Nanoparticles. Current Proteomics 2013;10:334- 340.
Inoue A, Kobayashi CI, Shinohara H, et al. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence. Int J Hematol 2018;108(4):365-370.
Dalgıç CT, Kaymaz BT, Özkan MC, et al. Investigating the Role of JAK/STAT Pathway on Dasatinib-Induced Apoptosis for CML Cell Model K562. Clin Lymphoma Myeloma Leuk 2015;15.
Li X, Pang J, Xue W, et al. Inducible SHP-2 activation confers resistance to imatinib in drugtolerant chronic myeloid leukemia cells. Toxicol Appl Pharmacol 2018;360:249-256.
Udelnow A, Kreyes A, Ellinger S, et al. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One 2011;6(5):e20143.
Lu ZN, Tian B, Guo XL. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol 2017;80(5):925-937.
Wang X, Liu C, Wang J, et al. Proton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer. Oncotarget 2017;8(35):58801-58808.
Lindner K, Borchardt C, Schöpp M, et al. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J ExpClin Cancer Res 2014;33:73.
Marino ML, Fais S, Djavaheri-Mergny M, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis 2010;1:e87.
Song T, Jeon HK, Hong JE, et al. Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer. Cancer Res Treat 2017;49(3):595-606.
Hou Y, Hu Q, Huang J, Xiong H. Omeprazole Inhibits Cell Proliferation and Induces G0/G1 Cell Cycle Arrest through Up-regulating miR-203a-3p Expression in Barrett's Esophagus Cells. Front Pharmacol 2018;8:968.
Patlolla JM, Zhang Y, Li Q, et al. Anticarcinogenic properties of omeprazole against human colon cancer cells and azoxymethaneinduced colonic aberrant crypt foci formation in rats. Int J Oncol 2012;40(1):170-5.